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Abstract To preserve the disequilibrium between ATP and
ADP necessary to drive cellular metabolism, enzymatic path-
ways rapidly convert ADP to adenosine and the downstream
purines inosine and hypoxanthine. During ischaemia, these
same pathways result in the production of purines. We per-
formed a prospective observational study to test whether
purine levels in arterial blood might correlate with brain is-
chaemia. We made real-time perioperative measurements, via
microelectrode biosensors, of the purine levels in untreated
arterial blood from 18 patients undergoing regional anaesthet-
ic carotid endarterectomy. Pre-operatively, the median purine
level was 2.4 μM (95% CI 1.3–4.0 μM); during the cross-
clamp phase, the purines rose to 6.7 μM (95% CI 4.7–
11.5 μM) and fell back to 1.9 μM (95% CI 1.4–2.7 μM) in
recovery. Three patients became unconscious during carotid
clamping, necessitating insertion of a temporary carotid shunt
to restore cerebral blood flow. In these, the pre-operative me-
dian purine level was 5.4 μM (range 4.7–6.1 μM), on
clamping, 9.6 μM (range 9.4–16.1 μM); during shunting, pu-
rines fell to below the pre-operative level (1.4 μM, range 0.4–
2.9 μM) and in recovery 1.8 μM (range 1.8–2.6 μM). Our
results suggest that blood purines may be a sensitive real-time
and rapidly produced indicator of brain ischaemia, even when
there is no accompanying neurological obtundation.
Keywords Adenosine . Brain Ischaemia . Carotid artery .
Cerebral blood flow . Neurosurgery
Introduction
Cellular metabolism is driven by the disequilibrium between
ATP and ADP [1]. While glycolysis and oxidative phosphor-
ylation ultimately generate ATP, enzymatic pathways exist in
cells to rapidly remove ADP and, in effect, convert it to aden-
osine and the downstream purines inosine and hypoxanthine.
For every molecule of ATP used by cellular processes, a mol-
ecule of adenosine is rapidly generated. Indeed, this can be
observed in real time in brain tissue in vitro [2]. This rapid
conversion of ADP to downstream metabolites helps to main-
tain the disequilibrium between ATP and ADP.
When cells are provided with insufficient substrates (e.g.
glucose or lactate) and/or O2 to make ATP, the enzymatic
systems that maximize the disequilibrium between ATP and
ADPwill rapidly cause the intracellular accumulation of aden-
osine and downstream purines. These metabolites can then
efflux via equilibrative transporters [3] into the extracellular
space. This ischemic production of extracellular adenosine
and purines has been observed in brain tissue both in vivo
and in vitro [4–14].
The blood-brain barrier (BBB) preserves the extracellular
environment of the brain to provide stable conditions for neu-
ral computation [15–17]. The BBB also regulates the efflux of
chemicals from the brain interstitial space to the blood via the
presence of specialized transporters [18]. While purine nucle-
osides can enter the brain from blood [19], it is by no means
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certain that the efflux of purines into the extracellular space
could be sufficient to result in an increase in their concen-
tration in blood. Although a few studies have examined
whether purine levels in blood increase during stroke [20]
and brain ischaemia [21], this has not been widely studied.
To address this issue, we have used a novel biosensor tech-
nology to examine the purine levels in sequential arterial
blood samples taken before, during and after the mild and
reversible brain ischaemia that is imposed during the cross-
clamp phase of awake carotid endarterectomy. This timed,
controlled, ischaemic insult to the brain provides an ideal
model in which to investigate how rapidly purines are re-
leased into the blood following the onset of ischaemia, and




Patients undergoing elective awake carotid endarterectomy
(CEA) were studied between May 2012 and November
2014. Patients were referred from the local TIA clinic, and
were assessed within a vascular surgical clinic. The surgery
was performed by a single surgeon (CHEI) at the University
Hospital Coventry and Warwickshire.
Surgical procedures
All CEAs were performed under loco-regional anaesthesia.
The anaesthetic was administered by one of two experienced
vascular anaesthetists with the aim being to personalize each
patient’s care, keeping them pain free and physiologically sta-
ble while using the minimum necessary sedation. Local an-
aesthetic drugs included bupivacaine and lignocaine, and the
short acting intravenous opioid remifentanil was used inter-
mittently, as was the sedative midazolam. A combination of
intravenous glycerol trinitrate and metaraminol were used to
maintain the systolic blood pressure between 110 and
180 mmHg. The surgical procedures were carried out with
3.5 times optical magnification, and a selective shunt and
patch policy was adopted. Prior to clamping of the carotid
arteries, intravenous heparin was administered, using a fixed
dose of 4000 units. Post-operatively, the patients recovered over-
night in a postanaesthetic care unit (PACU). Transcranial
Doppler was used to assess post-operative cerebral
microembolisation [22].
Neurological assessment
Shunting was determined by awake-testing, the indication
for shunting being profound neurological obtundation,
significant confusion, restlessness or inability to respond to
commands as determined by continuous clinical assessment
by the anaesthetist. Profound deterioration that occurred
within the first 90 s was handled by declamping the common
carotid artery and allowing the deficit to recover. The oper-
ation was then continued under general anaesthesia, and the
carotid shunt was inserted in a controlled fashion. A deficit
that occurred more than 90 s after cross-clamp, but before
the carotid arteriotomy (trial clamp for 5 min), was handled
by temporary clamp release. Once normal neurology was
restored, clamps were then reapplied allowing a shunt to
be inserted before the patient became obtunded a second
time [23].
Blood sampling
An arterial line was inserted under local anaesthetic
(lignocaine 1%) into the contralateral radial artery for routine
intraoperative and post-operative blood pressure monitoring.
Blood samples were drawn from this line in the anaesthetic
room prior to surgery, during the exposure phase, prior to
cross-clamping, during the cross-clamp phase, post clamp re-
lease, during closure and in the PACU.
Biosensor measurements
Measurements were performed in a prep room adjacent to the
operating theatre, giving real-time analysis at the point of care.
We used microelectrode biosensors previously described [24]
to measure the purines in fresh unprocessed blood. In brief,
these gold electrodes are coated with a Ruthenium Purple
layer which acts as a mediator to provide the necessary selec-
tivity against interferences such as ascorbate, urate and acet-
aminophen [24]. This allowed the accurate measurement of
purines in whole blood.
The purine sensor has an enzymatic layer containing a
cascade of three enzymes (Fig. 1a), which allowed it to
detect all of the substrates for these enzymes: adenosine,
inosine, hypoxanthine and xanthine [24, 25]. We made
amperometric measurements to detect the electroreduction
of peroxide produced by the final enzyme in the detection
cascade, xanthine oxidase. We also made Bnull^ biosensor
recordings as a control comparison. The null biosensors
were identical to the purine biosensors in all respects ex-
cept that they lacked the enzymatic cascade and therefore
could not respond to the purines [12].
We verified the accuracy of these sensors by measuring
known amounts of added purines in whole blood and plas-
ma (Fig. 1b). In whole blood, where red blood cells can take
up the purines and have abundant degradative enzymes on
their plasma membranes, the half-life of adenosine is report-
ed to be in the order of seconds while that of the down-
stream purines, inosine and hypoxanthine, can be in the
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order of minutes [26–28]. In whole blood, as might be ex-
pected, we only recovered about 54% of the added adeno-
sine (Fig. 1b). However, in plasma, where the blood cells
have been spun down, the purines are much more stable and
we measured about 88% of the added purines (Fig. 1b). As
the electrochemical interferences in whole blood and plasma
are the same, these results confirm that the biosensors are
highly selective [24]. They also emphasize the need for rap-
id point-of-care purine measurements to exploit purines as
indicators of clinical pathology as they are very unstable in
whole blood. Our ultimate aim in developing these biosen-
sors was to facilitate the use of purine measurements to
inform clinical decision-making processes. Whole blood is
routinely used clinically for a range of diagnostic tests at the
point of care. Therefore, despite the likely partial loss of
purines from whole blood, we performed this study on fresh
unprocessed blood to gain proof of principle of clinical
utility.
To measure purines in whole blood from the patients,
the null and purine biosensors were introduced into the
blood sample as soon as possible after sampling. They
were simultaneously polarized to the working potential
of −50 mV (versus Ag/AgCl), and the amperometric far-
adaic charging currents recorded (Fig. 1c). After 3 min,
the current value of the null sensor was subtracted from
the purine biosensor to give the Bpurine current^. This
was converted into a purine concentration by comparing
it to the current obtained from calibrating the sensors in a
known amount of adenosine (Fig. 1c).
Statistical presentation and analysis
All data are presented as medians with 95% confidence
limits—in the case of the smaller subgroups of the data (type
1, 2 and 3 patients), the 95% confidence limits are the same as
the range of the data. For the entire group, the data was
Fig. 1 Measurement of purines in arterial blood. a Enzymatic cascade
used to detect the blood purines. The enzymes are entrapped within a
layer on a Ruthenium Purple (RP)-coated gold electrode. b
Demonstration of analytical performance of biosensor in whole blood
(left) and plasma (right). A measurement of baseline purines was made
and then known concentration of adenosine added to the sample. The
open circles show the expected values of the measurements (baseline
purines plus the known added amount). The filled circles show the
amount of adenosine measured with the biosensor. c Example records
of sensor currents during blood measurements from a type 3 patient
showing the pre-operative blood purine level, shortly after carotid
clamping, and following recovery. The current records show the last
90 s of the measurement and are the difference between the purine and
null biosensors. The charging current in buffer (blue) indicates the Bzero
current^ level, the red trace shows the calibration with 10 μM adenosine
and the green trace is the measurement of the blood. The purine
concentration in blood is calculated by taking the difference between
the blood and buffer traces (black double-headed arrows), and
expressing this as a proportion of the difference between the calibration
and buffer traces
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analysed in two ways: (1) in a two-way Friedman ANOVA
comparing the preclamp, clamp and recovery purines across
the phases of the procedure within each patient; and (2) as
cumulative probability distributions of the purine levels at
each phase of the procedure—the medians and distributions
being compared via the Mann-Whitney U test and the
Kolmogorov-Smirnov tests respectively.
Results
Over a period of 2 years, we collected measurements from
18 patients. We first analysed the data obtained from these
patients as a single group. Overall, the median resting
purine level in blood, measured pre-operatively, was
2.4 μM (1.3 to 4.0 μM, Fig. 2). This value is comparable
to others in the literature which suggest that plasma con-
centrations of hypoxanthine/xanthine in humans (the pre-
dominant purines in blood) are in the range of 1–2 μM
[29, 30]. During carotid clamping, the blood purine levels
rose in every patient relative to the pre-operative baseline
(Fig. 2a). This increase was equally apparent when the
data for the blood levels in the pre-operative, clamp and
recovery periods were plotted as cumulative probability
distributions (i.e. treating the three conditions as
independent samples, Fig. 2b). The median purine level
in the clamp phase was 6.7 μM (4.7 to 11.5 μM). This
represents a 2.8-fold increase in concentration during the
clamp phase compared to the baseline. Following recov-
ery, the blood purines fell to the pre-operative baseline
(1.9 μM, 1.4 to 2.7 μM). Our analysis shows that within
a relatively short period following release of the clamp
(less than 1.5 h), the blood purine levels were indistin-
guishable from the pre-operative baseline.
We made repeated sequential measurements of blood pu-
rines throughout the carotid operative procedure. Inspection of
the profile of these measurements, combined with the con-
comitant neurological assessment of the patients, led us to
identify three patterns of perioperative purine release: type 1,
type 2 and type 3. Patients that displayed the type 1 and 2
patterns (7/18 and 8/18 respectively) displayed no major neu-
rological symptoms during carotid clamping. However, pa-
tients displaying the type 3 pattern of purine release (3/18)
rapidly became unconscious following the clamping of the
carotid artery.
During the type 1 pattern, the rise in purine levels was
sustained throughout the clamp period and reached its max-
imum towards the end of the clamp period (Fig. 3a). In
these patients, the median time to maximal purine blood
level was 21 min (14 to 29 min, Fig. 3d). The median
pre-operative purine level was 1.5 μM (0.8 to 4.0 μM) in
patients displaying the type 1 pattern. During carotid
clamping, purines rose to 5.7 μM (3 to 11.5 μM). This
represents a 3.8-fold increase in purine concentration during
the clamp phase compared to the baseline. During the re-
covery period, purines in blood fell to 1.8 μM (0.05 to
3.1 μM, Fig. 3a).
Patients displaying the type 2 pattern had pre-operative
baseline purines of 2.4 μM (0.7 to 5.6μM), and they exhibited
a transient pattern of purine release during the carotid
Fig. 2 Purines in arterial blood increase during carotid clamping. a Plot
of purine levels in the pre-operative (Pre), carotid clamp (Clamp) and
after recovery (Post) for each patient. In every patient, blood purine
levels increase relative to the pre-operative baseline. Statistical
comparison performed with the Friedman two-way ANOVA. b The
same data plotted as cumulative probability distributions for the pre-
operative, carotid clamp and recovery phases. Note that purine levels
return to pre-operative levels in the recovery phase. Statistical
comparison of medians performed with the Mann-Whitney U test. A
Kolmogorov-Smirnov comparison of the cumulative probabilities of
the pre-operative and clamp purine levels gives D = 0.6667, with
p = 0.000
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clamping. Their blood purines reached a peak (10.0 μM,
range 3.4 to 18.6 μM) much quicker than during the type 1
pattern (3 min, 1 to 16 min, p = 0.001, Mann-Whitney U test
compared to type 1 pattern, Fig. 3b, d). This was a 4.2-fold
increase in purine concentration during the clamp phase com-
pared to the baseline. After reaching this peak, the blood pu-
rine levels declined, but in six of eight cases remained higher
than the pre-operative baseline (3.2 μM, 0.9 to 13.6 μM). On
recovery, the purine levels returned to 2.2 μM (0.4 to 8.7 μM,
Fig. 3b).
During the type 3 pattern, patients rapidly became uncon-
scious following carotid clamping. Although we only ob-
served three patients displaying this type of pattern, they were
extremely interesting. The baseline purine levels were elevat-
ed compared to those seen during the type 1 and type 2 pat-
terns (5.4 μM, 3.9 to 6.7 μM, Figs. 1b and 3c). The purines
rose on clamping to 9.6 μM (9.1 to 22.5 μM). The increase in
purines following the clamp phase was 1.8-fold compared to
the baseline. During recovery following the procedure, they
fell to 1.8 μM (1.8 to 2.6 μM). This recovery value was lower
than the pre-operative baseline value. Importantly, when the
carotid artery was shunted to restore cerebral blood flow, the
blood purine levels dropped to below the pre-operative base-
line levels (1.4 μM, 0.4 to 2.9 μM, Fig. 3c). This observation
suggests that the brains of these patients were chronically
ischaemic owing to impeded carotid blood flow, which was
relieved initially by the temporary shunt (hence the purine
levels fell), and also in the longer term by the outcome of
the operation.
Discussion
CEA is performed to reduce the risk of a future stroke. An
integral part of the procedure is a temporary cross-clamping of
the carotid artery. As the timing and release of the carotid
clamp and hence the ischaemic insult are defined, this proce-
dure provides an excellent opportunity to test in human pa-
tients whether purine levels in blood are a marker of cerebral
ischaemia. In all 18 patients, we found that purine levels in
arterial blood rose within minutes of applying the carotid
clamp. In most patients, this occurred in the absence of any
overt neurological indication. This would suggest that the pu-
rines are a very sensitive measure of cerebral ischaemia.
Elevated purine levels were observed throughout the clamp
period, demonstrating that the purines are continually pro-
duced and released from the brain while the ischaemic insult
persists. Following release of the clamp, the blood purine
levels returned relatively quickly (within 1–2 h) to the pre-
clamp baseline. The purines are thus a relatively short-
lasting indication of cerebral ischaemia.
The ischaemic insult resulting from the carotid cross-
clamping is relatively mild and diffuse. Unlike a stroke, this
Fig. 3 Sequential blood purine measurements during carotid
endarterectomy reveal different profiles of purine release. a Left,
example of sequential measurements of blood purine levels during a
type 1 pattern. The pink rectangle indicates the timing and duration of
the carotid clamping. Right, plots of the pre-operative, carotid clamp and
recovery levels of purines for all patients displaying the type 1 pattern. b
Left, example of sequential measurements of blood purine levels during a
type 2 pattern. Right, plots of the pre-operative, carotid clamp and
recovery levels of purines for all patients displaying the type 2 pattern.
c Left, example of sequential measurements of blood purine levels during
a type 3 pattern. Note how purine levels rapidly dropped following
installation of the carotid shunt (arrow). Right, plots of the pre-
operative, carotid clamp and recovery levels of purines for all patients
displaying the type 3. d Histograms of the median time from carotid
clamp to maximal recorded purine release during the clamp phase for
patients displaying the type 1, 2 and 3 patterns. Error bars are upper
and lower quartiles
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insult will not be expected to be accompanied by either cell
death or damage to the blood-brain barrier. Nevertheless, in
every case during carotid cross-clamping, we detected elevat-
ed purines in arterial blood. This observation has two impor-
tant implications: (1) metabolically stressed, but otherwise
healthy, cells in the brain release purines into the extracellular
fluid; and (2) under physiological conditions, the blood-brain
barrier can transport sufficient purines to enable their detection
in blood. We suggest therefore that the purines could be used,
firstly, to detect the incidence of cerebral ischaemia from its
earliest origins and, secondly, to monitor the persistence of the
ischaemic insult and finally to assess resolution. As we have
used biosensors to measure the purines in freshly drawn un-
treated blood, our methods may comprise the basis of a point-
of-care blood test for the diagnosis and real-time monitoring
of stroke.
The release of adenosine during CEA has been previously
studied [21]. There are important methodological differences be-
tween the prior study and our study. Firstly, in the previous study
the patients underwent the procedure under general anaesthetic,
and neurological well-beingwas assessed indirectly by a somato-
sensory evoked potential in the cerebral cortex. Secondly, blood
samples were taken from the jugular venous outflow. Thirdly,
adenosine levels were measured by HPLC methods, which ne-
cessitated the storage and processing of the blood sample. The
previous study only observed adenosine release if there was a
loss of the somatosensory evoked potential following carotid
cross-clamping.
In our study, we have used a more sensitive measurement
method that uses peripheral blood sampling, and does not re-
quire the processing or storage of blood thus giving real-time
measurements. We observed increased purine release in every
patient undergoing the procedure, and were able to construct a
profile of the release pattern via sequential measurements.
Nevertheless, our study supports the conclusion of the previous
study that purines are a sensitive marker of cerebral ischaemia.
We separated the perioperative purine profiles observed in
patients into three groups based on the dynamics of purine re-
lease and whether the patients lost consciousness. Although this
separation is purely empirical, we tentatively propose an under-
lying mechanistic basis. Patients displaying the type 1 pattern
exhibited a rather slower increase in blood purines that was rel-
ativelymodest in magnitude. Theymay therefore have retained a
higher ability to compensate for the loss of blood flow from the
ipsilateral carotid artery by enhancing flow from the contralateral
side via the Circle of Willis than the patients displaying the other
patterns of purine release. During the type 1 pattern, we propose
that the compensatory flow has a rapid-onset coincident with the
restriction of blood flow on the ipsilateral side, and this has the
effect of both slowing and limiting the purine rise during carotid
clamping.
Patients displaying the type 2 pattern may retain some abil-
ity for contralateral compensation; however, we suggest that
the onset of the compensation is delayed—hence the tendency
to higher initial increases in blood purines, and the later fall of
purine levels during the clamp phase.
During the type 3 pattern, patients rapidly lost conscious-
ness during carotid clamping. We suggest that they may have
lost the ability to compensate with enhanced blood flow from
the contralateral side. Furthermore, as their blood purines were
high even at the pre-operative stage, their brains may be under
chronic ischaemic stress. As the blood purine levels fell to
below baseline levels within minutes of shunt insertion, the
shunting may restore cerebral oxygen delivery either to, or
even above, pre-clamp levels.
There is abundant evidence connecting brain ischaemia
with the release of purines [31]. For example, in isolated brain
slices, glucose-oxygen deprivation (an in vitro model of is-
chaemia) stimulates release of adenosine and downstream pu-
rines [7, 9, 11, 14]. In animal models, middle cerebral artery
occlusion also causes adenosine release [8, 32, 33]. In
humans, two studies suggest that adenosine levels in blood
are elevated during CEA [21], and following stroke and TIA
[20]. Nevertheless, the utility of purines as a measurement of
brain ischaemia has largely been overlooked. One complica-
tion with the standard techniques to measure blood purines is
that purine half-life in blood is only a few minutes. Accurate
measurement of blood purines is thus difficult, as it requires
rapid separation of cells and plasma, and inhibition of any
reuptake mechanisms or degradative processes. It is perhaps
this latter point that has made exploiting purines in clinical
diagnosis difficult to date.
We believe that our methods overcome this drawback and
have the potential to provide a point-of-care device for rapid
measurement of purines in freshly drawn unprocessed blood.
This may unlock the potential for purine measurements to be
used to assess neurological status in stroke patients. How
might this methodology change clinical practice? We suggest
that purine measurements could be used to prioritize patients
for CEA: patients with higher resting purine levels might ben-
efit from earlier surgery. It would also appear that such pa-
tients might be more likely to require intraoperative shunting
and, if required, shunt patency could be confirmed via the
effect on arterial purine levels. Although we have not studied
stroke patients, there are obvious potential applications here
too. For example, a point-of-care device for measuring purines
in the hands of first responders would enable the rapid identi-
fication of stroke, and complement prehospital tests for stroke,
such as the Face Arms Speech Test, and CT scans, to give
more accurate diagnosis. The faster and more accurate identi-
fication of stroke patients should in turn lead to more rapid
treatment with better outcomes. In addition, as the purines are
only produced during ongoing ischaemia, repeated measure-
ments may allow assessment in real time as to whether the
ischaemic injury is clearing or worsening without necessitat-
ing further brain scans.
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We note that ischaemia, anywhere in the body, has the
potential to cause elevation of purines in blood. Cardiac is-
chaemia is of particular interest as purine efflux during this
condition is well documented [34, 35]. Purine efflux from the
brain can also occur during traumatic brain injury [36] and
seizures [31, 37, 38]. Optimal use of purines as a diagnostic
aid will therefore always depend on other clinical measures
and the overall clinical context of the patient.
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